1.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000686574, SWOG-S1011, S1011, NCT01224665
|
|
2.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00730, RTOG 0524, U10CA021661, NCT00238420
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00170, PHII-75, CDR0000492014, N01CM00071, N01CM00038, CCC-PHII-75, 7435, NCI-7435, NCT00365157
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AEZS-108-046, EProst # 20091095, NCT01234519
|
|
5.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-1339, NCT01342172
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 19811, NCT01520038
|
|
7.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-0933, NCT00756639
|
|
8.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000616858, RTOG-0712, NCT00777491
|
|
9.
|
Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090214, 09-C-0214, NCT00978250
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FER-GU-026, NCI-2010-01910, NCT01031420
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HOG GU10-147, NCT01215136
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOBL204, NCT01215877
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-208, NCT01261728
|
|
15.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13943, CP20-0902, I4Y-IE-JCDC, NCT01282463
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GCO#10-1341, NCT01331824
|
|
17.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 60 and over Sponsor: NCI Protocol IDs: 110146, 11-C-0146, NCT01339000
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: N10-1, NCT01353222
|
|
19.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 4B-10-4, NCI-2011-01108, NCT01382706
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11D.392, 2011-52, NCT01437488
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-071, NCT01589094
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: ERP-GU-052, NCI-2012-00906, IRB#12-015, NCT01611662
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-191, NCT01622660
|
|
24.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU12-160, NCT01780545
|
|
25.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-031, NCT01104350
|